Literature DB >> 7351817

Adverse reactions associated with ticrynafen use.

D A McLain, F J Garriga, O S Kantor.   

Abstract

Three hypertensive patients receiving ticrynafen, a new uricosuric diuretic, experienced adverse reactions. One patient experienced acute renal failure, the second experienced a renal stone, and the third had a fatal hemorrhage while receiving anticoagulation therapy with warfarin sodium. All complications can be explained by known actions of the drug and are preventable. However, these reactions illustrate the potential hazards from widespread substitution of ticrynafen for thiazide diuretics in the treatment of hypertension.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7351817

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  6 in total

1.  The risks of asymptomatic hyperuricaemia and the use of uricosuric diuretics.

Authors:  M W Johnson; W E Mitch
Journal:  Drugs       Date:  1981-03       Impact factor: 9.546

2.  Warfarin exposure and calcification of the arterial system in the rat.

Authors:  A M Howe; W S Webster
Journal:  Int J Exp Pathol       Date:  2000-02       Impact factor: 1.925

Review 3.  Drug-Induced Kidney Stones and Crystalline Nephropathy: Pathophysiology, Prevention and Treatment.

Authors:  Michel Daudon; Vincent Frochot; Dominique Bazin; Paul Jungers
Journal:  Drugs       Date:  2018-02       Impact factor: 9.546

4.  Ticrynafen and hydrochlorothiazide. A comparison in hypertensive patients with renal impairment.

Authors:  B T Emmerson; P J Renshaw; P J Ravenscroft; I Denham; S Schey
Journal:  Eur J Clin Pharmacol       Date:  1982       Impact factor: 2.953

Review 5.  Drug-induced renal calculi: epidemiology, prevention and management.

Authors:  Michel Daudon; Paul Jungers
Journal:  Drugs       Date:  2004       Impact factor: 9.546

6.  Multicentre controlled trial of tienilic acid in hyperuricaemic, hypertensive subjects, with intensive monitoring of liver function.

Authors: 
Journal:  Br J Clin Pharmacol       Date:  1983-05       Impact factor: 4.335

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.